Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov;79(17):1905-1909.
doi: 10.1007/s40265-019-01218-6.

Trifarotene: First Approval

Lesley J Scott  1
Affiliations
Review

Trifarotene: First Approval

Lesley J Scott. Drugs. 2019 Nov.

Abstract

Topical trifarotene (Aklief®) is a first-in-class, fourth-generation retinoid [selective retinoic acid receptor (RAR)-γ agonist] being developed by Galderma Research and Development LLC for the treatment of acne vulgaris. In October 2019 trifarotene received its first global approval in the USA for the topical treatment of acne vulgaris in patients 9 years of age and older. This article summarizes the milestones in the development of trifarotene leading to its first global approval for acne vulgaris.

PubMed Disclaimer

References

    1. Br J Dermatol. 2018 Aug;179(2):442-456 - PubMed
    1. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1736-1741 - PubMed
    1. Am J Clin Dermatol. 2019 Jun;20(3):345-365 - PubMed
    1. Am J Clin Dermatol. 2018 Feb;19(1):51-66 - PubMed
    1. J Am Acad Dermatol. 2019 Jun;80(6):1691-1699 - PubMed

MeSH terms

LinkOut - more resources